Vaccine Info

UB-313 Migraine Vaccine

Authored by
Staff
Share

UB-313 Migraine Vaccine Description

UB-313 is a novel immunotherapeutic vaccine candidate targeting calcitonin gene-related peptide (CGRP) for the preventive treatment of migraine.

CGRP causes vasodilation and neurogenic inflammation and is known to play an important role in migraine pathophysiology.

UB-313 is designed to trigger the production of antibodies that inhibit CGRP in patients with chronic and episodic migraine to reduce migraine frequency and severity.

UB-313 has entered a Phase 1 clinical trial.

UB-313 Migraine Vaccine News

September 13, 2022 - Vaxxinity, Inc. (Nasdaq: VAXX) announced that the first subjects have been dosed in a Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin gene-related peptide (CGRP), for the preventive treatment of migraine.

Clinical Trials

No clinical trials found